Delivery Order SPE2DB24D2101-SPE2DB25FKPDU
- Not listed
- The Defense Logistics Agency awarded a $34,278.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 15, 2025, and performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $64,939.14 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 11, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $5,405.62 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 10, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The pharmaceutical product will be delivered to the company's headquarters location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,926.54 for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price, non-set-aside award that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $32,533.93 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). The contract, which is not set-aside, is set to conclude by September 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $16,902.11 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 13, 2025, with completion scheduled for August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $17,816.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 10, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $66,535.75 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside contract with a completion date of July 30, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's distribution center in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $50,306.61 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This non-competitive delivery order, which is scheduled for completion by August 29, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPDUDelivery Order
The Defense Logistics Agency awarded a $26,921.10 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 4, 2025, and represents a child order under AmerisourceBergen's larger prime contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where the distributor maintains its operational headquarters. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies to support Defense Health Agency operations and other federal healthcare customers. The Trelegy Ellipta product—a combination respiratory medication used in chronic obstructive pulmonary disease treatment—exemplifies the company's role in delivering specialty pharmaceutical commodities across multiple therapeutic domains to support military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.9k | 9/3/25 |